Halozyme Therapeutics Total Liabilities 2010-2024 | HALO

Halozyme Therapeutics total liabilities for the quarter ending December 31, 2024 were $1.700B, a 3.04% increase year-over-year.

  • Halozyme Therapeutics total liabilities for 2024 were $1.7B, a 3.04% increase from 2023.
  • Halozyme Therapeutics total liabilities for 2023 were $1.649B, a 1.33% decline from 2022.
  • Halozyme Therapeutics total liabilities for 2022 were $1.672B, a 84.22% increase from 2021.

Quarterly Chart

Click on chart icon to view chart
Click on table icon to view table

Quarterly - YOY Change

Click on chart icon to view chart
Click on table icon to view table

Annual

Click on chart icon to view chart
Click on table icon to view table

Annual % Change

Click on chart icon to view chart
Click on table icon to view table
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B
Bio-Rad Laboratories (BIO.B)$6.3B